ThromboGenics and VIB found oncology company

April 14, 2015 News BioVox

Oncurious is a new oncology company that will perform clinical trials for the development of TB-403. This compound is a new promising agent for the treatment of brain tumors in children. Alongside ThromboGenics, VIB (Flemish Institute for Biotechnology) will be a shareholder.

Medulloblastoma is a rare, but life-threatening, brain tumor that  occurs mostly in children. In this type of cancer, PLGF (placental growth factor) is (over-)expressed. TB-403 is a monoclonal antibody directed against PLGF. Animal studies were promising and the safety profile is favorable. TB-403 also has  potential as a treatment for other pediatric tumours. Johan Cardoen, executive at VIB, hopes to make Oncurious into a leading oncology company. 

Read more about this topic in our soon to be published Insights article.

Avatar photo

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts